Review of Sarcoidosis in a Province of South Korea from 1996 to 2014.
10.4046/trd.2017.80.3.291
- Author:
Min Seok KIM
1
;
Cheol Kyu PARK
;
Hong Joon SHIN
;
Hyeong Won SEO
;
Jinsun CHANG
;
Seong AHN
;
Tae Ok KIM
;
Jung Hwan LIM
;
In Jae OH
;
Yong Soo KWON
;
Yu Il KIM
;
Sung Chul LIM
;
Young Chul KIM
Author Information
1. Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea. Kyc0923@jnu.ac.kr
- Publication Type:Original Article
- Keywords:
Sarcoidosis;
Bronchoscopy;
Endoscopic Ultrasound-Guided Fine Needle Aspiration
- MeSH:
Biopsy;
Bronchoscopy;
Diagnosis;
Electronic Health Records;
Endoscopic Ultrasound-Guided Fine Needle Aspiration;
Humans;
Incidence;
Jeollanam-do;
Korea*;
Lymph Nodes;
Needles;
Remission, Spontaneous;
Sarcoidosis*;
Steroids;
Ultrasonography
- From:Tuberculosis and Respiratory Diseases
2017;80(3):291-295
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Since the introduction of endobronchial ultrasound (EBUS)–guided transbronchial needle aspiration (TBNA) of mediastinal lymph nodes, the incidence of histopathologically-confirmed sarcoidosis has increased. METHODS: The electronic medical records of Chonnam National University (CNU) Hospital and CNU Hwasun Hospital (CNUHH) were searched for confirmed cases of sarcoidosis diagnosed between 1996 and 2014. Cases were selected using a combination of clinical, radiological, and pathological evidence. Of 115 cases with the relevant disease codes, 16 cases were excluded, as they had not been confirmed pathologically or had no definitive clinical features of sarcoidosis. RESULTS: Among 99 cases of confirmed sarcoidosis, only nine patients were diagnosed with sarcoidosis before 2008; the rest were diagnosed from 2008 onward, after the introduction of EBUS-TBNA. EBUS-TBNA was used in 75.8% of patients, open surgical biopsy in 13.2%, and mediastinoscopic biopsy in 5.1%. At the time of diagnosis, 42.4% of sarcoidosis cases were at stage I, 55.6% at stage II, and 2% at stage III. Spontaneous remission of sarcoidosis was observed in 33.3% of cases, and stable disease in 37.4%; systemic steroid treatment was initiated in 23.2% of cases. Of the patients treated with systemic steroids, 69.6% showed improvement. The median duration of steroid treatment was 5 months. CONCLUSION: Following the introduction of EBUS-TBNA, the number of newly diagnosed sarcoidosis patients has increased. Clinical features of sarcoidosis were similar to those previously reported. Spontaneous remission occurred in about one-third of patients, while one-fourth of patients required systemic steroid treatment.
